If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
New bone formation is observed on the trabecular and cortical (periosteal and/or endosteal) bone surfaces (Forteo Package Insert, 2012).
trabecular bone volume,
trabecular bone connectivity,
structure model index, and
cortical thickness (Jiang, 2003).
Dynamic histomorphometric analyses conducted on iliac crest biopsies from PMW with osteoporosis demonstrated that teriparatide stimulates bone formation on all bone envelopes (cancellous, endocortical, intracortical, and periosteal) as early as 3 months and remains sustained for the full 24 months of therapy. (Dempster, 2016b; Dempster, 2016c).
Radionuclide bone scan imaging has demonstrated a direct metabolic effect of teriparatide on the whole skeleton and various sub-skeletal sites (Moore, 2012).
New bone formed during teriparatide treatment has lower more heterogeneous mineral content; a property consistent with younger bone age (Dempster, 2016a).
Enclosed Prescribing Information
The published references below are available upon request by contacting 1-800-LillyRx.
FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
Dempster DW, Roschger P, Misof BM, et al. Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study [published online March 30, 2016]. J Bone Miner Res. 2016a.
Dempster DW, Zhou H, Recker RR, et al. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial [published online March 8, 2016]. J Bone Miner Res. 2016b.
Dempster DW, Zhou H, Recker RR, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016c;101(4):1353-1363.
Date of Last Review: March 08, 2017